Researchers found that lenacapavir reduced almost 100% reduction new HIV infections among participants who received it as a ...

Unfortunately, the Trump administration and the Republican majorities in Congress are putting access to lifesaving ...

WHO endorses biannual injectable Lenacapavir for HIV prevention. This long-acting PrEP offers hope for high-risk groups and ...

Lenacapavir, a long-acting injectable pre-exposure prophylaxis, has been recommended by the WHO to help protect high-risk ...

The World Health Organisation (WHO) released new guidelines recommending the use of injectable lenacapavir (LEN) twice a year ...

Thousands of adults age 50-plus are diagnosed with HIV every year, but an expanding menu of medications can help prevent ...

Kenya is set to roll out the long-acting injectable HIV Pre-Exposure prophylaxis (PrEP) Lenacapavir by January 2026 following ...

The World Health Organization now recommends lenacapavir, a twice-yearly injectable HIV prevention drug, especially for high-risk groups. This endorse ...

LEN is the first long-acting PrEP product that requires only two injections per year, offering an appealing alternative to ...

WHO director general Tedros Adhanom Ghebreyesus says this new drug—which only needs to be injected twice a year—is the next ...

Innovation, inclusion, and urgency  define Kigali HIV conference ANALYSIS | RONALD MUSOKE | When the 13th International AIDS ...